ライブラリ登録: Guest
Critical Reviews™ in Oncogenesis

年間 4 号発行

ISSN 印刷: 0893-9675

ISSN オンライン: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

The Tumor Microenvironment: A Target for Combination therapy of Breast Cancer

巻 18, 発行 1-2, 2013, pp. 115-133
DOI: 10.1615/CritRevOncog.v18.i1-2.70
Get accessGet access

要約

Cancer immunotherapy is in the midst of a major paradigm shift from an approach primarily focused on attacking tumor cells to a strategy also targeting the tumor microenvironment (TME). This strategy is designed for the use of combination therapies, several of which are reviewed here. Particular emphasis is placed on targeting such components of the TME as tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) overexpressing specific therapy targets such as Legumain, an asparaginyl endopeptidase, proto-oncogene Fra-1, transcription factor Stat3 and fibroblast activation protein (FAP) as well as HER-2, respectively. The use of DNA vaccines directed against some of these targets overexpressed on both breast tumor cells as well as TAMs and CAFs in the TME results in the elimination of tumor growth, progression, metastasis and recurrence in mouse tumor models. This type of cancer therapy is significantly improved in efficacy by a strategy specifically designed to combine immunotherapies, including DNA vaccines, with a novel chemotherapy featuring highly effective nanoparticle-mediated drug delivery, specifically targeted to tumor cells as well as key components of the TME, leading to its modulation and subsequent elimination of tumor growth, metastasis, and, most importantly, suppression of tumor recurrence.

によって引用された
  1. Eccles Suzanne A, Aboagye Eric O, Ali Simak, Anderson Annie S, Armes Jo, Berditchevski Fedor, Blaydes Jeremy P, Brennan Keith, Brown Nicola J, Bryant Helen E, Bundred Nigel J, Burchell Joy M, Campbell Anna M, Carroll Jason S, Clarke Robert B, Coles Charlotte E, Cook Gary JR, Cox Angela, Curtin Nicola J, Dekker Lodewijk V, dos Santos Silva Isabel, Duffy Stephen W, Easton Douglas F, Eccles Diana M, Edwards Dylan R, Edwards Joanne, Evans D Gareth, Fenlon Deborah F, Flanagan James M, Foster Claire, Gallagher William M, Garcia-Closas Montserrat, Gee Julia M W, Gescher Andy J, Goh Vicky, Groves Ashley M, Harvey Amanda J, Harvie Michelle, Hennessy Bryan T, Hiscox Stephen, Holen Ingunn, Howell Sacha J, Howell Anthony, Hubbard Gill, Hulbert-Williams Nick, Hunter Myra S, Jasani Bharat, Jones Louise J, Key Timothy J, Kirwan Cliona C, Kong Anthony, Kunkler Ian H, Langdon Simon P, Leach Martin O, Mann David J, Marshall John F, Martin Lesley Ann, Martin Stewart G, Macdougall Jennifer E, Miles David W, Miller William R, Morris Joanna R, Moss Sue M, Mullan Paul, Natrajan Rachel, O’Connor James PB, O’Connor Rosemary, Palmieri Carlo, Pharoah Paul D P, Rakha Emad A, Reed Elizabeth, Robinson Simon P, Sahai Erik, Saxton John M, Schmid Peter, Smalley Matthew J, Speirs Valerie, Stein Robert, Stingl John, Streuli Charles H, Tutt Andrew N J, Velikova Galina, Walker Rosemary A, Watson Christine J, Williams Kaye J, Young Leonie S, Thompson Alastair M, Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer, Breast Cancer Research, 15, 5, 2013. Crossref

  2. Ding Hui, Helguera Gustavo, Rodríguez José A., Markman Janet, Luria-Pérez Rosendo, Gangalum Pallavi, Portilla-Arias Jose, Inoue Satoshi, Daniels-Wells Tracy R., Black Keith, Holler Eggehard, Penichet Manuel L., Ljubimova Julia Y., Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer, Journal of Controlled Release, 171, 3, 2013. Crossref

  3. Bakiri L, Macho-Maschler S, Custic I, Niemiec J, Guío-Carrión A, Hasenfuss S C, Eger A, Müller M, Beug H, Wagner E F, Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression, Cell Death & Differentiation, 22, 2, 2015. Crossref

  4. Nelson Edward L, HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium, Clinical Investigation, 4, 7, 2014. Crossref

  5. Liu Ze, Xiong Min, Gong Junbo, Zhang Yan, Bai Nan, Luo Yunping, Li Luyuan, Wei Yuquan, Liu Yanhua, Tan Xiaoyue, Xiang Rong, Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment, Nature Communications, 5, 1, 2014. Crossref

  6. Zhao Haishan, Wang Zhe, Wu Huizhe, Xiao Qinghuan, Yao Weifan, Wang Enhua, Liu Yong, Wei Minjie, STAT3 genetic variant, alone and in combination with STAT5b polymorphism, contributes to breast cancer risk and clinical outcomes, Medical Oncology, 32, 1, 2015. Crossref

  7. Stetler-Stevenson William G., Gavil Noah Veis, Normalization of the tumor microenvironment: evidence for tissue inhibitor of metalloproteinase-2 as a cancer therapeutic, Connective Tissue Research, 55, 1, 2014. Crossref

  8. Cojoc Monica, Mäbert Katrin, Muders Michael H., Dubrovska Anna, A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms, Seminars in Cancer Biology, 31, 2015. Crossref

  9. Convit J., Montesinos H., Oviedo H., Romero G., Maccarone B., Essenfeld E., Convit A., Palacios L. E., Autologous tumor lysate/Bacillus Calmette–Guérin immunotherapy as an adjuvant to conventional breast cancer therapy, Clinical and Translational Oncology, 17, 11, 2015. Crossref

  10. Lei Jieping, Rudolph Anja, Moysich Kirsten B., Behrens Sabine, Goode Ellen L., Bolla Manjeet K., Dennis Joe, Dunning Alison M., Easton Douglas F., Wang Qin, Benitez Javier, Hopper John L., Southey Melissa C., Schmidt Marjanka K., Broeks Annegien, Fasching Peter A., Haeberle Lothar, Peto Julian, dos-Santos-Silva Isabel, Sawyer Elinor J., Tomlinson Ian, Burwinkel Barbara, Marmé Frederik, Guénel Pascal, Truong Thérèse, Bojesen Stig E., Flyger Henrik, Nielsen Sune F., Nordestgaard Børge G., González-Neira Anna, Menéndez Primitiva, Anton-Culver Hoda, Neuhausen Susan L., Brenner Hermann, Arndt Volker, Meindl Alfons, Schmutzler Rita K., Brauch Hiltrud, Hamann Ute, Nevanlinna Heli, Fagerholm Rainer, Dörk Thilo, Bogdanova Natalia V., Mannermaa Arto, Hartikainen Jaana M., Van Dijck Laurien, Smeets Ann, Flesch-Janys Dieter, Eilber Ursula, Radice Paolo, Peterlongo Paolo, Couch Fergus J., Hallberg Emily, Giles Graham G., Milne Roger L., Haiman Christopher A., Schumacher Fredrick, Simard Jacques, Goldberg Mark S., Kristensen Vessela, Borresen-Dale Anne-Lise, Zheng Wei, Beeghly-Fadiel Alicia, Winqvist Robert, Grip Mervi, Andrulis Irene L., Glendon Gord, García-Closas Montserrat, Figueroa Jonine, Czene Kamila, Brand Judith S., Darabi Hatef, Eriksson Mikael, Hall Per, Li Jingmei, Cox Angela, Cross Simon S., Pharoah Paul D. P., Shah Mitul, Kabisch Maria, Torres Diana, Jakubowska Anna, Lubinski Jan, Ademuyiwa Foluso, Ambrosone Christine B., Swerdlow Anthony, Jones Michael, Chang-Claude Jenny, Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium, Human Genetics, 135, 1, 2016. Crossref

  11. Slany Astrid, Bileck Andrea, Muqaku Besnik, Gerner Christopher, Targeting breast cancer-associated fibroblasts to improve anti-cancer therapy, The Breast, 24, 5, 2015. Crossref

  12. Wu Mei, Shao Guang-Rui, Zhang Fei-Xue, Wu Wen-Xiu, Xu Ping, Ruan Zheng-Min, Legumain Protein as a Potential Predictive Biomarker for Asian Patients with Breast Carcinoma, Asian Pacific Journal of Cancer Prevention, 15, 24, 2015. Crossref

  13. Chen Hongyuan, Liu Xiao, Clayman Eric S., Shao Fangyuan, Xiao Manshan, Tian Xuyan, Fu Wuyu, Zhang Caiyun, Ruan Bibo, Zhou Pengjun, Liu Zhong, Wang Yifei, Rui Wen, Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and itsin vitroEffects on SiHa Cervical Cancer Cells Under Hypoxic Conditions, Chemical Biology & Drug Design, 86, 4, 2015. Crossref

  14. Jackson Kenneth W., Christiansen Victoria J., Yadav Vivek R., Silasi-Mansat Robert, Lupu Florea, Awasthi Vibhudutta, Zhang Roy R., McKee Patrick A., Suppression of Tumor Growth in Mice by Rationally Designed Pseudopeptide Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase, Neoplasia, 17, 1, 2015. Crossref

  15. Liu Yonglei, Zhang Jingling, Sun Xiangjun, Li Meilin, EMMPRIN Down-regulating miR-106a/b Modifies Breast Cancer Stem-like Cell Properties via Interaction with Fibroblasts Through STAT3 and HIF-1α, Scientific Reports, 6, 1, 2016. Crossref

  16. Poggi Alessandro, Giuliani Massimo, Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment, Vaccines, 4, 4, 2016. Crossref

  17. Song Xu, Wan Zhuoya, Chen Tijia, Fu Yao, Jiang Kejun, Yi Xiaoli, Ke Huan, Dong Jianxia, Yang Liuqing, Li Lin, Sun Xun, Gong Tao, Zhang Zhirong, Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment, Biomaterials, 108, 2016. Crossref

  18. S. Franco Sara, Szczesna Karolina, Iliou Maria S., Al-Qahtani Mohammed, Mobasheri Ali, Kobolák Julianna, Dinnyés András, In vitro models of cancer stem cells and clinical applications, BMC Cancer, 16, S2, 2016. Crossref

  19. Gu Xiaoting, Lu Chunxiao, He Dongxu, Lu Yangfan, Jin Jian, Liu Dequan, Ma Xin, Notch3 negatively regulates chemoresistance in breast cancers, Tumor Biology, 37, 12, 2016. Crossref

  20. Qiao Aixiu, Gu Feng, Guo Xiaojing, Zhang Xinmin, Fu Li, Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications, Frontiers of Medicine, 10, 1, 2016. Crossref

  21. Liu Xiu-Jun, Zheng Yan-Bo, Li Yi, Wu Shu-Ying, Zhen Yong-Su, Anto Ruby John, A Multifunctional Drug Combination Shows Highly Potent Therapeutic Efficacy against Human Cancer Xenografts in Athymic Mice, PLoS ONE, 9, 12, 2014. Crossref

  22. Shen Shiyang, Liu Meng, Li Teng, Lin Shiqi, Mo Ran, Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy, Biomaterials Science, 5, 8, 2017. Crossref

  23. Yang Feng, Aubele Michaela, Walch Axel, Gross Eva, Napieralski Rudolf, Zhao Shuo, Ahmed Nancy, Kiechle Marion, Reuning Ute, Dorn Julia, Sweep Fred, Magdolen Viktor, Schmitt Manfred, Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer, Biological Chemistry, 398, 10, 2017. Crossref

  24. Foster Christian, Watson Andre, Kaplinsky Joseph, Kamaly Nazila, Improved Targeting of Cancers with Nanotherapeutics, in Cancer Nanotechnology, 1530, 2017. Crossref

  25. Sameni Mansoureh, Cavallo-Medved Dora, Franco Omar E., Chalasani Anita, Ji Kyungmin, Aggarwal Neha, Anbalagan Arulselvi, Chen Xuequn, Mattingly Raymond R., Hayward Simon W., Sloane Bonnie F., Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ, Breast Cancer Research, 19, 1, 2017. Crossref

  26. YIN WEIWEI, ZHANG JING, JIANG YUMIN, JUAN SHEN, Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice, Experimental and Therapeutic Medicine, 8, 4, 2014. Crossref

  27. Zhao Juan, Wan Zhuoya, Zhou Chuchu, Yang Qin, Dong Jianxia, Song Xu, Gong Tao, Hyaluronic Acid Layer-By-Layer (LbL) Nanoparticles for Synergistic Chemo-Phototherapy, Pharmaceutical Research, 35, 10, 2018. Crossref

  28. Meguid Eiman Abdel, El-Hashash Ahmed, Cancer Stem Cells and Their Therapeutic Applications, in Stem Cells for Cancer and Genetic Disease Treatment, 2018. Crossref

  29. Cao Duo, Liang Lin, Xu Yixin, Sun Ji, Lei Meng, Wang Man, Wei Yahui, Sun Zhenliang, Tumor associated macrophages and angiogenesis dual-recognizable nanoparticles for enhanced cancer chemotherapy, Nanomedicine: Nanotechnology, Biology and Medicine, 14, 3, 2018. Crossref

  30. Li Yongfu, Wei Yuhan, Tang Wenjun, Luo Jingru, Wang Minghua, Lin Haifeng, Guo Hong, Ma Yuling, Zhang Jun, Li Qin, Association between the degree of fibrosis in fibrotic focus and the unfavorable clinicopathological prognostic features of breast cancer, PeerJ, 7, 2019. Crossref

  31. Lowe Devin B., Finke James H., Garcia Jorge A., Storkus Walter J., Vaccines in RCC: Clinical and Biological Relevance, in Renal Cell Carcinoma, 2015. Crossref

  32. Behrens Diana, Rolff Jana, Hoffmann Jens, Predictive In Vivo Models for Oncology, in New Approaches to Drug Discovery, 232, 2015. Crossref

  33. Jiang Guan-Min, Xu Wei, Du Jun, Zhang Kun-Shui, Zhang Qiu-Gui, Wang Xiao-Wei, Liu Zhi-Gang, Liu Shuang-Quan, Xie Wan-Ying, Liu Hui-Fang, Liu Jing-Shi, Wu Bai-Ping, The application of the fibroblast activation protein α-targeted immunotherapy strategy, Oncotarget, 7, 22, 2016. Crossref

  34. Zhao Ting, Zhou Hongli, Lei Lei, Guo Chenqi, Yang Qin, Gong Ting, Sun Xun, Song Xu, Gong Tao, Zhang Zhirong, A new tandem peptide modified liposomal doxorubicin for tumor “ecological therapy”, Nanoscale, 12, 5, 2020. Crossref

  35. Upreti Meenakshi, Jyoti Amar, Johnson Sara E., Swindell Elden P., Napier Dana, Sethi Pallavi, Chan Ryan, Feddock Jonathan M., Weiss Heidi L., O’Halloran Thomas V., Evers B. Mark, Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer, Oncotarget, 7, 27, 2106. Crossref

  36. Wang Fang‑Tao , Sun Wei , Zhang Jing‑Tao , Fan Yue‑Zu , Cancer‑associated fibroblast regulation of tumor neo‑angiogenesis as a therapeutic target in cancer (Review), Oncology Letters, 2019. Crossref

  37. Jain Sanyog, Raza Kaisar, Agrawal Ashish Kumar, Vaidya Ankur, Targeting breast cancer, in Nanotechnology Applications for Cancer Chemotherapy, 2021. Crossref

  38. Peng Hui, Wang Jia-Hui, Guo Feng, Zhu Fang-Fang, Wen Zu-Jun, Zhong Hai-Jun, Liang De-Sheng, Legumain protease-activated tuftsin-functionalized nanoparticles for dual-targeting TAMs and cancer chemotherapy, Colloids and Surfaces B: Biointerfaces, 197, 2021. Crossref

  39. Zhao Yajie, Pu Chunrui, Liu Zhenzhen, Exploration the Significance of a Novel Immune-Related Gene Signature in Prognosis and Immune Microenvironment of Breast Cancer, Frontiers in Oncology, 10, 2020. Crossref

  40. Olivares-Urbano María Auxiliadora, Griñán-Lisón Carmen, Marchal Juan Antonio, Núñez María Isabel, CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer, Cells, 9, 7, 2020. Crossref

  41. Zhang Lijing, Qi Yingqiu, Min Huan, Ni Chen, Wang Fei, Wang Bin, Qin Hao, Zhang Yinlong, Liu Guangna, Qin Yue, Duan Xixi, Li Feng, Han Xuexiang, Tao Ning, Zhang Lirong, Qin Zhihai, Zhao Ying, Nie Guangjun, Cooperatively Responsive Peptide Nanotherapeutic that Regulates Angiopoietin Receptor Tie2 Activity in Tumor Microenvironment To Prevent Breast Tumor Relapse after Chemotherapy, ACS Nano, 13, 5, 2019. Crossref

  42. Tang Yisi, Fan Wufa, Chen Guihua, Zhang Meng, Tang Xueping, Wang Hairui, Zhao Pengfei, Xu Qin, Wu Zhibing, Lin Xiaoxi, Huang Yongzhuo, Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment, Nano Today, 40, 2021. Crossref

  43. Zhao Chunqian, Chen Hongyuan, Wang Fengshan, Zhang Xinke, Amphiphilic self-assembly peptides: Rational strategies to design and delivery for drugs in biomedical applications, Colloids and Surfaces B: Biointerfaces, 208, 2021. Crossref

  44. Yingjuan Wang, Li Zhang, Wei Cao, Xiaoyuan Wang, Identification of prognostic genes and construction of a novel gene signature in the skin melanoma based on the tumor microenvironment, Medicine, 100, 21, 2021. Crossref

  45. Zhao Tian, Liu Yujie, Hao Yanfei, Zhang Wei, Tao Li, Wang Dong, Li Yuyin, Liu Zhenxing, McKenzie Edward A, Zhao Qing, Diao Aipo, Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis, Investigational New Drugs, 39, 2, 2021. Crossref

  46. Qi Qi, Obianyo Obiamaka, Du Yuhong, Fu Haian, Li Shiyong, Ye Keqiang, Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis, Journal of Medicinal Chemistry, 60, 17, 2017. Crossref

  47. Gu Xiaoyan, Gao Yunzhen, Wang Ping, Wang Lixin, Peng Haibao, He Yuanzhi, Liu Ying, Feng Nianping, Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treatment of breast cancer metastasis, Journal of Controlled Release, 333, 2021. Crossref

  48. Miller Jared T., Vitro Caitlin N., Fang Siteng, Benjamin Samantha R., Tumey L. Nathan, Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers, Bioconjugate Chemistry, 32, 4, 2021. Crossref

  49. Linton Samuel S., Sherwood Samantha G., Drews Kelly C., Kester Mark, Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine, WIREs Nanomedicine and Nanobiotechnology, 8, 2, 2016. Crossref

  50. Parisi Francesca, Tesi Matteo, Millanta Francesca, Gnocchi Marzia, Poli Alessandro, M1 and M2 tumour-associated macrophages subsets in canine malignant mammary tumours: An immunohistochemical study, Research in Veterinary Science, 136, 2021. Crossref

  51. Wang Fang‐Tao, Li Xin‐Ping, Pan Mu‐Su, Hassan Mohamed, Sun Wei, Fan Yue‐Zu, Identification of the prognostic value of elevated ANGPTL4 expression in gallbladder cancer‐associated fibroblasts, Cancer Medicine, 10, 17, 2021. Crossref

  52. Liang De-Sheng, Wen Zu-Jun, Wang Jia-Hui, Zhu Fang-Fang, Guo Feng, Zhou Jian-Liang, Xu Jian-Jun, Zhong Hai-Jun, Legumain protease-sheddable PEGylated, tuftsin-modified nanoparticles for selective targeting to tumour-associated macrophages, Journal of Drug Targeting, 30, 1, 2022. Crossref

  53. Wu Aihua, Chen Yingzhi, Wang Hairui, Chang Ya, Zhang Meng, Zhao Pengfei, Tang Yisi, Xu Qin, Zhu Zhuangzhi, Cao Yang, Huang Yongzhuo, Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy, Acta Pharmaceutica Sinica B, 11, 11, 2021. Crossref

  54. Horvath D., Brutovsky B., A new conceptual framework for the therapy by optimized multidimensional pulses of therapeutic activity. The case of multiple myeloma model, Journal of Theoretical Biology, 454, 2018. Crossref

  55. Sun Xuezheng, Sandhu Rupninder, Figueroa Jonine D., Gierach Gretchen L., Sherman Mark E., Troester Melissa A., Benign Breast Tissue Composition in Breast Cancer Patients: Association with Risk Factors, Clinical Variables, and Gene Expression, Cancer Epidemiology, Biomarkers & Prevention, 23, 12, 2014. Crossref

  56. Sobolev Vladimir V., Khashukoeva Asiat Z., Evina Olga E., Geppe Natalia A., Chebysheva Svetlana N., Korsunskaya Irina M., Tchepourina Ekaterina, Mezentsev Alexandre, Role of the Transcription Factor FOSL1 in Organ Development and Tumorigenesis, International Journal of Molecular Sciences, 23, 3, 2022. Crossref

  57. Taeb Shahram, Ashrafizadeh Milad, Zarrabi Ali, Rezapoor Saeed, Musa Ahmed Eleojo, Farhood Bagher, Najafi Masoud, Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy, Current Cancer Drug Targets, 22, 1, 2022. Crossref

  58. Wang Song, Luo Zifeng, Zhou Xinke, Wang Chong, Luo Yuanwei, Yi Nian, Liao Yu Ling, Multifunctional Nanoparticles Loaded with Vascular Endothelial Growth Factor Inhibitors and MED1 siRNA to Inhibit Breast Cancer Progression by Targeting Tumor-Associated Macrophages and Breast Cancer Cells, Journal of Biomedical Nanotechnology, 17, 12, 2021. Crossref

  59. Casalino Laura, Talotta Francesco, Cimmino Amelia, Verde Pasquale, The Fra-1/AP-1 Oncoprotein: From the “Undruggable” Transcription Factor to Therapeutic Targeting, Cancers, 14, 6, 2022. Crossref

  60. Chung Bomy Lee, Kaplinsky Joseph, Langer Robert, Kamaly Nazila, Delivery of Cancer Nanotherapeutics, in Nanotheranostics for Cancer Applications, 5, 2019. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain